Powerhouse Type 2 Diabetes Medication Exenatide Aids Patients with Weight Loss

Powerhouse Type 2 Diabetes Medication Exenatide Aids Patients with Weight Loss

ExenatideExenatide, CAS number 141758-74-9 is an injectable prescription medication that helps to improve blood sugar, or glucose control in adults with type 2 diabetes mellitus. Exenatide, derived from a compound found in the saliva of the Gila monster, a large lizard native to the southwestern US, is a functional analog of Glucagon-Like Peptide-1 (GLP-1), a naturally occuring peptide. Exenatide is most effective when it is used alongside a treatment plan composed of a diet and exercise program.  Known as the synthetic injectable Byetta, which is marketed by Amylin Pharmaceuticals Inc., exenatide has a patent expiration of December 1, 2016. Exenatide can be safely used with metformin, a sulfonylurea drug, a thiazolidinedione, or Lantus {insulin glargine}.  While exenatide is similar to insulin, it is not actually insulin. In the class of drugs deemed incretin mimetics, exenatide mimics the action of a hormone called glucagon-like peptide1, also called GLP-1, lowering insulin and blood sugar.

Gila MonsterAs a twice daily injectable, exenatide offers not only blood sugar control assistance to patients, but it also often leads to weight loss. Exenatide is believed to suppress the appetite, and delay the movement of food from the stomach into the small intestine. These actions can cause patients taking exenatide to feel full longer, and faster, leading to less food consumption overall.  The most common side effect of exenatide is nausea, which is usually mild to moderate and improves with time in most people. Exenatide has rarely caused kidney failure or harmful inflammation of the pancreas, also termed pancreatitis. With blood sugar levels improving for many patients as early as the first day of treatment with exenatide, many patients have hailed this medical treatment a surprising success. In contrast to the weight gain that often accompanies many diabetes medications, which ultimately lead to a worsening of this disease, exenatide has the opposite effect. Many patients have reported that exenatide has actually reversed their diabetic condition, as their weight loss and insulin control from this drug has been effectual and substantial.

Clinical studies have shown that the 10-microgram dose of exenatide {Byetta} helped four times as many patients reach their blood sugar goal when compared to other comparable diabetes medications. In addition to this positive finding, patients who received 10-micrograms of exenatide in clinical trials lost at least 6 pounds in a 24 week period. Another plus for exenatide is its ease of use. Doses are pre-measured, in easy-to-use pens. LGM Pharma is a provider of the API exenatide, as well as the TEVA API exenatide for research and development purposes.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service